Overview

Safety and Efficacy Study in Infant With SBS

Status:
Terminated

Trial end date:
2018-03-22

Target enrollment:

Participant gender:

Summary

The objective of this clinical study is to evaluate the efficacy and safety of NTRA-9620 compared with placebo in pediatric subjects (aged 28 weeks postmenstrual age to 52 weeks old) with SBS following surgical resection

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Elgan Pharma Ltd.
Nutrinia